Vir Biotechnology grants CFO 150K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vir Biotechnology, Inc. granted EVP, Chief Financial Officer Aziz Sawaf 75,000 restricted stock units (RSUs) and stock options covering 150,000 common shares on November 15, 2026. The options have a $9.96 exercise price and expire November 14, 2036. Twenty-five percent of each award vests on November 15, 2027; the remaining RSUs vest in three equal annual installments, while the remaining options vest and become exercisable in 36 equal monthly installments.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F3 | 150,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1, F2 | 75,000 | $0.00 | $0.00 |
Footnotes (3)
- F1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- F2. 25% of the RSUs will vest on November 15, 2027, and the remaining RSUs will vest in three equal annual installments thereafter.
- F3. 25% of the shares subject to the stock option will vest and become exercisable on November 15, 2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter.
Key Figures
Key Terms
restricted stock units (RSUs) financial
Equity Incentive Plan financial
exercisable technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How do Aziz Sawaf's VIR equity awards vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.